Top Gainer Stocks Today July 13 2026 | Energy Biotech Movers

Monday, July 13, 2026 was not a good day for the bulls — unless you were in energy stocks, pharma defensives, or select biotech names that bucked the tape entirely. The S&P 500 shed 0.79% to close at 7,515.34. The Nasdaq Composite lost 1.55% to finish at 25,873.18. The Dow fell 138.37 points (-0.26%) to 52,498.64. Semiconductors got crushed again. And President Donald Trump reinvented the session’s narrative entirely with a single Truth Social post.

But within the carnage, a different story was playing out in 10 stocks that moved higher — some emphatically — while everything around them was sliding. Here are today’s top gainers with the context, catalysts, and forward-looking data every trader needs.

📊 Today’s Market Close — The Context Behind the Gainers

What drove Monday’s decline: At approximately mid-session, President Trump posted on Truth Social: “We are reinstating THE IRANIAN BLOCKADE… The U.S.A. will be, from this point forward, known as ‘THE GUARDIAN OF THE HORMUZ STRAIT,’ but as such, and as a matter of FAIRNESS, will be reimbursed, at the rate of 20% on all cargo shipped.” Crude oil immediately surged. Tech stocks — already pressured by SK Hynix’s post-Nasdaq-debut selloff in Korea — fell further. But 10 names finished sharply in the green. Here they are.

🟢 1. Biogen (NASDAQ: BIIB) — Today’s Biggest S&P 500 Gainer

Day Move: +4.96% | Sector: Biotech / Neurology | Catalyst: Upbeat Analyst Calls

Biogen was Monday’s most outstanding gainer in large-cap territory — up nearly 5% on a day when the broad market was bleeding. The catalyst: upbeat analyst calls on the company’s neurological portfolio, specifically around commercial launch trajectory updates for its Alzheimer’s treatment franchise.

Why today’s move matters:

• Biogen’s lecanemab (branded as Leqembi), developed in partnership with Eisai, is one of the only disease-modifying Alzheimer’s treatments approved by the FDA
• Alzheimer’s affects approximately 6.9 million Americans — a massive, growing, underserved market
• On Monday, analyst commentary highlighted that early real-world usage data is tracking above prescription rate expectations, which pushed buy-side desks into the stock
• Biogen has been in a multi-year repositioning phase since the controversial aducanumab (Aduhelm) withdrawal, and lecanemab’s commercial progress is the primary redemption narrative
• The stock is one of the few healthcare names directly positioned at the intersection of aging demographics and pharmaceutical innovation

The setup heading into Tuesday:

With CPI data arriving Tuesday at 8:30 AM and five mega-bank earnings simultaneously, pharmaceutical defensives like BIIB tend to hold value in volatile macro environments. Any further analyst upgrade or real-world lecanemab data update would be a secondary catalyst.

🟢 2. Madrigal Pharmaceuticals (NASDAQ: MDGL) — MASH Drug Momentum Keeps Running

Day Move: +4.16% | Trending: Stocktwits #9 | Q1 2026 Revenue: $311.34M (+127% YoY)

Madrigal is the rare biotech that’s going UP on a down day — and it’s doing it for entirely fundamental reasons. The company’s drug Rezdiffra (resmetirom), the first FDA-approved MASH treatment, is in full commercial launch phase and posting revenue growth that most pharmaceutical companies only dream about.

The data that keeps MDGL in focus:

• Q1 2026 net revenue: $311.34M — beat the $300.92M estimate and grew 127% year-over-year
• 42,250+ patients now on Rezdiffra globally — prescriber adoption running ahead of expectations
• European approval achieved — Rezdiffra is now approved in the EU without requiring a liver biopsy for prescribing — a unique commercial differentiator
• BofA: Neutral, target $542 | Truist: Buy, target $709 | Evercore ISI: Outperform, target $649 | Analyst consensus: ~$671
• Rezdiffra annual Wholesale Acquisition Cost (WAC): ~$49,000 — compelling for a potentially $35 billion addressable market by 2030
• Morningstar: Trading within fairly valued range — no extreme premium, just a commercial-stage biotech executing flawlessly

Why Monday specifically saw a move:

With the broader market risk-off on Iran geopolitics, healthcare and biotech names with commercial revenue — not just pipeline hope — attracted rotational capital. Madrigal, with its recurring prescription revenue and expanding patient base, is precisely the kind of name institutions buy when macro uncertainty rises.

Key Data Snapshot:

🛢️ 3. Energy Sector — The Day’s Defining Trade: XOM, CVX, DVN, OXY All Surge

XLE ETF: +2–3% | WTI Crude: +8.78% to $77.68 | Biggest Oil Move Since 2020

When Trump announced the reinstatement of the Iranian shipping blockade with a 20% cargo fee on all Strait of Hormuz traffic, the oil market immediately repriced. Crude oil surged 8.78% to $77.68/barrel in the biggest single-session oil move since 2020. Every major energy stock in the S&P 500 ended the day sharply higher.

What the blockade announcement means:

• The Strait of Hormuz handles approximately 20% of global oil trade — any disruption immediately tightens the global supply picture
• Iran sends approximately 1.7–2.0 million barrels per day through the strait; blockade restrictions reduce global supply sharply
• The 20% cargo fee effectively makes alternative routing (Cape of Good Hope bypass, Saudi East-West Pipeline) more economically competitive — but those routes take significantly longer and add to costs

Energy gainers today:

• ExxonMobil (XOM): Up significantly; world’s largest oil major benefits directly from WTI near $77+
• Chevron (CVX): Similar move; upstream production economics dramatically improve at $77/barrel
• Devon Energy (DVN): Higher-beta domestic E&P; WTI at $77 is $9 above Devon’s fiscal breakeven
• Occidental Petroleum (OXY): Warren Buffett’s preferred energy name; highly leveraged to oil price moves

For context: The energy sector (XLE) was the only S&P 500 sector with material gains today — a direct beneficiary of geopolitical risk that hurt virtually everything else in the portfolio.

🟢 4. BlackRock (NYSE: BLK) — Pre-Earnings Positioning Ahead of Wednesday

Day Move: +1.61% | Reports: Wednesday, July 15 | Sector: Asset Management

BlackRock’s +1.61% gain is one of the more strategically significant moves of the day — not because of any news, but because of what’s coming. The world’s largest asset manager reports Q2 2026 results Wednesday morning, and institutional money is rotating into BLK ahead of what’s expected to be a strong quarterly print.

Why BLK is positioned for a beat:

• The S&P 500 gained +9.5% in H1 2026, growing AUM through market appreciation alone — regardless of net flows, market gains add billions to BlackRock’s fee base
• The AI infrastructure rally drove significant demand for thematic ETFs — BlackRock’s iShares lineup (SOXX, IGV, AI-focused products) saw record inflows in Q1 and Q2
• BlackRock’s private credit and alternatives platform continues to grow at double-digit rates — the fastest-growing segment of the asset management industry
• Analyst consensus expects AUM above $12 trillion — a new record if confirmed Wednesday

🟢 5. MAGS ETF (Roundhill Magnificent 7 ETF) — The Defensive Tech Play Holding Green

Day Move: +1.38% | Holdings: AAPL, MSFT, GOOGL, AMZN, META, NVDA, TSLA

The MAGS ETF — which tracks the Magnificent Seven mega-cap tech stocks — managed a +1.38% gain on a day when the broader Nasdaq fell 1.55%. This divergence signals institutional preference for the most liquid, largest-balance-sheet tech names as a relative safety trade when the broader tape turns risk-off.

What held MAGS up:

• Apple (AAPL: +0.74%): Resilience driven by strong services revenue expectations for Q2; iPhone supply chain updates suggest no major disruptions from Iran
• Meta Platforms: Benefit of the “Meta Compute” cloud narrative — if Meta is selling AI compute, it’s a new revenue stream that analysts are still modeling upward
• The Magnificent Seven companies collectively have over $500 billion in net cash — fortress balance sheets that attract capital during geopolitical risk-off moves

🟢 6. Merck (NYSE: MRK) — The Pharma Defensive Everyone Wants Before CPI Day

Day Move: +1.22% | Trending on StockTwits: #1 | Dividend Yield: ~2.5–3%

Merck’s Stocktwits trending position reflected a very specific pre-CPI trade: in uncertain inflation environments, pharmaceutical companies with dividend yields and blockbuster drug revenue make ideal hedges. Merck’s Keytruda (pembrolizumab) remains the world’s best-selling cancer drug — generating approximately $25+ billion in annual revenue — with additional new indications expanding its addressable patient population.

Keytruda context:

• FDA approved additional indications in 2026 for earlier-stage lung cancer and perioperative use in bladder cancer
• New competitor checkpoint inhibitors have not materially dented Keytruda’s market share
• Merck’s Winrevair (sotatercept) for pulmonary arterial hypertension is in its commercial launch phase — a second major revenue driver coming online
• The company’s dividend history makes it attractive for institutional investors seeking income in a period when rate policy remains uncertain

🟢 7. Apple (NASDAQ: AAPL) — Quiet Resilience in a Brutal Tech Session

Day Move: +0.74% | Context: Tech sector -1.55% (Nasdaq)

Apple’s +0.74% gain on a day when the Nasdaq fell 1.55% tells a story about where institutional money wants to hide when the broader tech trade breaks down. Following last quarter’s significant decline on price hike concerns, Apple is beginning to show signs of stabilization.

Why AAPL is recovering:

• Apple raised MacBook and iPad prices by $100–$300 in late June — initially seen as demand-destructive; analysts are now modeling that premium consumers absorbed the increases better than feared
• Services revenue (App Store, Apple TV+, Apple Pay, Apple Care) continues to grow regardless of hardware price cycles
• Any improvement in US-China trade relations or Iran ceasefire news is a direct positive for Apple’s supply chain
• AAPL’s forward P/E at current levels represents a meaningful discount to its 2025 peak multiples

🟢 8. TSM (Taiwan Semiconductor Manufacturing Company, NYSE: TSM) — The Chip Stock Standing Tall

Day Move: +0.65% | Context: Semiconductor sector broadly down | TSMC = the exception

In a session where SK Hynix fell 9%, Micron fell 4%, and SanDisk crashed 12%, TSMC’s +0.65% gain stands out as a vote of confidence in the differentiated chip story. TSMC’s position as the world’s only viable manufacturer of the most advanced semiconductors (3nm and below) gives it pricing power that commodity memory chip makers don’t have.

Why TSMC held up:

• TSMC recently reported June revenue: up significantly YoY, confirming that AI chip orders for N3 and N2 process nodes remain strong
• Apple is TSMC’s largest customer — Apple’s stability today helped TSMC sentiment
• ASML’s upcoming earnings (Wednesday) will confirm whether EUV machine orders support continued TSMC capacity expansion
• TSMC’s semiconductor manufacturing business is structurally immune to the memory oversupply fears that hurt MU and SNDK

🟢 9. Broadcom (NASDAQ: AVGO) — The Most Resilient Chip Name in Today’s Selloff

Day Move: +0.28% | Context: Chip sector broadly declining | XLV Broad resilience

Broadcom’s marginal gain on a brutal chip day — when SanDisk fell 12% and Micron fell 4% — reflects its fundamentally different business mix. Unlike pure memory chip makers, Broadcom generates revenue from networking silicon, wireless chips, infrastructure software (via its VMware acquisition), and custom AI accelerators.

Broadcom’s specific resilience factors:

• Custom AI chip revenue from hyperscaler agreements (Google, Meta, Apple) doesn’t depend on memory pricing dynamics
• VMware integration continues to generate recurring software revenue that is uncorrelated to semiconductor spot pricing
• Broadcom’s Q3 AI chip sales guidance of $16B (even though it missed the $17.2B estimate) still represents significant growth
• The company’s dividend growth record makes it a natural institution hold even in sector-level volatility

🟢 10. XLV / Healthcare Sector ETF — The Quiet Winner of the Risk-Off Day

Day Move: Positive across the sector | Catalyst: Biotech rotation + defensive bid

Healthcare sector stocks broadly gained Monday as investors rotated out of semiconductors and AI infrastructure plays into more defensive positions. The XLV ETF — which holds names like UnitedHealth, J&J, Eli Lilly, Abbott, Pfizer, and BIIB — benefited from the same defensive capital that lifted BIIB, MRK, and MDGL individually.

Key sector tailwinds today:

• Risk-off rotation from tech to healthcare on geopolitical uncertainty
• Ahead of Tuesday’s CPI data, high-growth tech positioning is being trimmed
• UnitedHealth (UNH) earnings Thursday create positioning interest across the sector
• J&J reports Wednesday — pre-earnings institutional buying common in the sector

📅 Today’s Session in Summary

Tomorrow (Tuesday) sets the tone for the rest of the week: CPI at 8:30 AM, five mega-bank earnings before open, and Kevin Warsh’s first congressional testimony at 10 AM. The energy trade and biotech positioning from today could extend — or completely reverse — depending on what inflation prints at 8:30 tomorrow morning.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades. Prices and percentage moves referenced reflect July 13, 2026 intraday and closing conditions and are approximate. Geopolitical events, particularly US-Iran developments, can cause material price changes within hours of publication. Past performance is not indicative of future results.

Further Reading:

• Motley Fool — July 13, 2026 Market Today
• CNBC Market Update — July 13, 2026
• Biogen Investor Relations — Leqembi Commercial Update
• Madrigal Pharmaceuticals Investor Relations — Rezdiffra Launch
• EIA Crude Oil Market Update — Strait of Hormuz Impact
• Stocktwits Trending Board
• BlackRock Investor Relations — Q2 2026 Preview
• Bureau of Labor Statistics — Tuesday CPI Release

About The Author

Kasia Davis

See author's posts